FMC 2025 Q1 Earnings Misses Targets as Net Income Worsens 403%

FMC Corporation reported its fiscal 2025 Q1 earnings on April 30, 2025. The company posted a net loss of $16 million, down significantly from Q1 2024. Despite expectations, FMC maintained its full-year guidance, forecasting revenue between $4.15 billion and $4.35 billion and adjusted EBITDA of $870 million to $950 million. The company remains optimistic about the second half of the year, anticipating growth in sales and adjusted EBITDA, despite current challenges.

Revenue
The total revenue of FMC decreased by 13.8% to $791.40 million in 2025 Q1, down from $918 million in 2024 Q1.

Earnings/Net Income
FMC's losses deepened to $0.12 per share in 2025 Q1 from a loss of $0.02 per share in 2024 Q1, representing a 500% wider loss. The company's net loss widened to $-15.60 million in 2025 Q1, showing a 403.2% increase from the $-3.10 million loss in 2024 Q1. The EPS performance indicates significant challenges.

Price Action
The stock price of FMC has edged up 2.52% during the latest trading day, climbed 6.61% during the most recent full trading week, and edged down 0.69% month-to-date.

Post Earnings Price Action Review
Backtest results analyzing the impact of earnings report metrics on FMC show that while the 3-Day win rate for revenue is relatively high at 50.64%, it drops to 48.48% for EPS and 51.36% for net income. Over a 10-Day period, the win rate is highest for net income at 51.36%, followed by revenue at 50.64%, and EPS at 48.48%. The 30-Day win rate is lowest across all three metrics, ranging from 48.48% to 50.64%. The maximum return observed was -0.04% over the 30-Day period, suggesting that earnings metrics generally have a negative or neutral impact on FMC's stock price in the short term. Investors should consider these alongside other factors and market conditions before making decisions.

CEO Commentary
"First quarter sales were largely in line with our expectations," said Pierre Brondeau, Chairman and Chief Executive Officer of FMC Corporation. He noted that the company’s focus on increasing product-on-the-ground while controlling sales allowed FMC to align inventory levels with customer targets. Brondeau highlighted that lower revenue was driven by a 9 percent price decline, primarily due to adjustments in specific contracts, alongside a 4 percent headwind from foreign currency. He emphasized a cautious approach in Q2 to facilitate substantial growth in the second half of the year.

Guidance
FMC Corporation reaffirms its full-year 2025 guidance, expecting revenue between $4.15 billion and $4.35 billion. The adjusted EBITDA outlook remains at $870 million to $950 million, with anticipated incremental tariff costs of $15 million to $20 million factored into the guidance. For the second quarter, the revenue is projected to be between $940 million and $1.10 billion, reflecting a decline of 2 percent at the midpoint compared to Q2 2024. Adjusted EBITDA is forecasted to account for modest volume growth offset by price and foreign exchange headwinds.

Additional News
FMC Corporation announced a regular quarterly dividend of 58 cents per share, payable on July 17, 2025, to shareholders of record as of June 30, 2025. The dividend reflects FMC's commitment to returning value to shareholders despite current earnings challenges. Furthermore, Frontier Medicines unveiled new preclinical data for FMC-220, showcasing its potential in cancer treatments and plans for an IND filing in the second half of 2025. Additionally, FMC Corporation maintained its full-year 2025 outlook despite Q1 revenue declines, betting on a stronger performance in the latter half of the year.